Biophytis SA announced that the Company entered into a new loan structure with Kreos Capital. The ?10 million total loan was concluded on November 19, 2021 and includes four tranches of respectively ?2.5 million, ?3.0 million, ?2.5 million and ?2.0 million. The two first tranches were drawn upon signing of the contract on November 19, 2021, the third tranche can be drawn up to December 31, 2021, and the last tranche can be drawn up to March 31, 2022. Besides, Kreos Capital will receive Biophytis? share warrants (?bon de souscription d?action? or ?BSA?) for a total of approximately ?1 million. Over the ?10M, ?7.75 million will be in straight bonds, and ?2.25 million will be in convertible bonds. Interest shall accrue on the principal moneys outstanding at a fixed interest rate of (10.00%) per annum for straights bonds and at a fixed interest rate of (9.50%) per annum for convertible bonds. The straight bonds will be repaid in 36 monthly instalments, after a deferral repayment of the nominal amount until April 2022. The Company shall repay the convertible bonds at their principal amount at the latest March 31, 2025, unless they are converted before into shares, at the option of Kreos Capital, at a fixed conversion price of ?0,648 (except in the event that the Company distributes dividends). The loan is a senior unsubordinated financing. As security of its obligations, the Company has pledged certain assets, to the benefit of Kreos Capital.